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Edited by Gerrit van MeerAbstract ATP-binding cassette (ABC) transporters are inte-
gral membrane proteins that couple ATP hydrolysis to the trans-
port of various molecules across cellular membranes. Found in
both prokaryotes and eukaryotes, a sub-group of these transport-
ers are involved in the eﬄux of hydrophobic drugs and lipids,
causing anti-microbial and chemotherapeutic multidrug resis-
tance. In this review, we examine recent structural and functional
analysis of the ABC transporter MsbA and implications on the
mechanism of multidrug eﬄux.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Clinical multidrug resistance (MDR) represents a critical
challenge in the treatment of human cancers and bacterial
infections [1–5]. Drug-resistant bacterial strains that cause
gonorrhea, pneumonia, cholera, and tuberculosis are wide-
spread and diﬃcult to treat. In humans, a similar mechanism
of MDR is a major reason for the failure of numerous chemo-
therapeutics in the treatment of cancers. A major cause of bac-
terial and cancer drug resistance is the over-expression of a
battery of MDR transporters that extrude toxic drug com-
pounds out of the cell.
MDR transporters can be divided into two classes based on
their source of energy: ATP-binding cassette (ABC) transport-
ers which couple the hydrolysis of ATP to substrate transport
across the cell membrane, and secondary transporters, which
use proton gradients to facilitate transport. Over the past num-
ber of years, X-ray crystallographic studies of ABC transport-
ers have added tremendous insight into understanding the
underlying mechanics of ATP-mediated substrate transport
to the already large body of genetic, biochemical and biophys-
ical work. At the same time, many new questions have emergedAbbreviations: ABC, ATP binding cassette; ICD, intercellular domain;
LPS, lipopolysaccharide; MDR, multidrug resistance; NBD, nucleo-
tide binding domain; P-gp, P-glycoprotein; TMD, transmembrane
binding domain; EM, electron microscopy
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doi:10.1016/j.febslet.2005.11.033that remain to be answered. Here, we review the three X-ray
crystal structures of MsbA in the context of other structural
and functional work.2. ABC MDR transporters
ABC transporters compose one of the largest superfamilies
of proteins [6,7]. Bacteria expresses two classes of transporters:
importers and exporters, which are responsible for transport-
ing a wide variety of substrates such as lipids, sugars, amino
acids, peptides, ions and hydrophobic drugs. Eukaryotic gen-
omes, on the other hand, only encode exporters (for a review
of bacterial ABC transporters, see Davidson [8]; for a review
of human ABC transporters, see Dean [9]). Exporters are
responsible for conferring MDR phenotypes. ABC transport-
ers are composed minimally of four core structural domains:
two nucleotide-binding domains (NBDs) and two transmem-
brane domains (TMDs). ABC transporters in bacteria either
express each of the four domains as separate subunit polypep-
tides, or a dimer with the NBD fused to the TMD. Eukaryotic
ABC transporters are expressed either as dimers or as a single
polypeptide containing all four domains. Structural divergence
within the various subgroups of ABC transporters is promi-
nent in the TMDs and likely reﬂects the large diversity of
substrate speciﬁcity. The NBD, which is the hallmark of this
transporter family, is more highly conserved. Functional
MDR, has been identiﬁed in lipid ﬂippases such as the human
transporters P-gp (P-glycoprotein/MDR1/ABCB1) and
ABCG2 as well as bacterial transporters LmrA and MsbA,
both in vitro and in vivo [10–17] (Table 1).3. MsbA, a lipopolysaccharide ﬂippase/MDR homologue
MsbA, an essential ABC transporter in Gram-negative bac-
teria, is a lipid ﬂippase that transports lipid A and lipopolysac-
charide (LPS), the major component in the bacterial outer
membrane, from the inner to the outer leaﬂet of the inner mem-
brane [18,19]. In vitro studies have demonstrated that MsbA is
an ATPase that is speciﬁcally stimulated by lipid A and LPS
molecules [20] and has overlapping substrate speciﬁcities with
both LmrA and P-gp [16]. A recent paper by Woebking et al.
has shown that MsbA interacts with multiple drugs, and con-
fers an increase in the level of resistance to the antibiotic eryth-
romycin when expressed in Gram-positive Lactococcus lactis
[17]. Thus, MsbA expressed in an LPS-free environment is ablished by Elsevier B.V. All rights reserved.
Table 1
Transporter MDR substrates Known non-MDR substrates Reference








MsbA Duanorubicin, doxorubicin, vinblastine,
erythromycin, TPP+, ethidium bromide
Lipid A, LPS [16,17]
Hoechst
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lying transport mechanism between MsbA, LmrA and P-gp is
likely conserved, with an evolutionary ﬁne tuning in the speci-
ﬁcity for the native substrates such as LPS, in the case ofMsbA.
In addition, MsbA from E. coli shares one of the highest pro-
tein sequence similarities to P-gp (36% identical to the NH2-ter-
minal half of human P-gp) further indicating a common
evolutionary origin for the mechanics of amphipathic and
hydrophobic substrate transport.4. Driving translocation with ATP hydrolysis
The NBD, which is also called an ABC, is the unifying fea-
ture of the ABC transporter family. The high resolution X-ray
crystal structures of isolated NBDs (HisP [21], MalK [22,23],
MJ1276 [24], MJ0796 [25,26], TAP1 [27] GlcV [28], HlyB
[29,30] and CFTR [31,32], to name a few) have shown three
conserved structural subdomains: an F1-type ATPase binding
core containing the Walker A (P-loop) and Walker B ATPase
motifs, an antiparallel b-sheet subdomain that positions the
base and ribose moieties of the nucleotide, and an a-helical
subdomain that contains the ABC signature or LSGGQ motif
distinct to the ABC transporter family (Fig. 1).
A picture of the various conformations along the ATP
hydrolysis cycle has begun to emerge from the combination
of structures from isolated NBDs and intact ABC transport-
ers. The structure of the full-length bacterial vitamin B12
ABC importer, BtuCD, shows two interacting NBDs forming
a dimer in the absence of nucleotide [33] (Fig. 1A). The iso-
lated NBD structure of ATP-bound MJ0796, reveals an active
site architecture with the P-loop and the LSGGQ signature
motif anchoring and aligning the bound ATP molecules toFig. 1. Structures of the NBDs of ABC transporters. (A) BtuCD (1L7V). Th
loop or Walker A (blue), Q-loop (green), LSGGQ motif (magenta), ATP (yel
MJ0796 (1L2T). (C) MsbA in complex with ADP and orthovanadate (orang
The C-terminal domain is highlighted in green. All pdb codes are in parenthform two composite active sites [26] (Fig. 1B). Finally, the
NBDs from the ADP, orthovanadate structure of intact
ABC transporter MsbA, form a dimer interface similar to both
BtuCD and MJ0796, however the LSGGQ motif does not
interact with the nucleotide and vanadate (Fig. 1C) [34]. In
the MsbA ADP-vanadate structure, the presence of only one
bound nucleotide per NBD dimer is observed and consistent
with numerous studies of ABC transporters such as P-gp [35]
and MalK [36,37] in which vanadate enters the active site of
only one NBD to form a complex with ADP. Although all
of the solved X-ray structures of intact ABC transporters
(BtuCD and MsbA) were solved at medium resolution and
therefore a degree of uncertainty may be present in the side
chain positions, the value of these structures is to provide in-
sight into gross conformational changes associated with the
ATP hydrolysis cycle in the NBDs.
Based on the available structural data, we propose that open-
ing and closing of the NBD dimer interface drives conforma-
tional changes in the TMDs and therefore translocation of
substrate. The conformation of NBDs in the BtuCD structure
may represent the initial state of dimerization in which the
NBDs are in close contact. ATP binding likely decreases the
distance between the interacting NBDs and drives conforma-
tional changes in the TMDs. This tight dimerization as
observed in the MJ0796 structure could be broken during
hydrolysis by buildup of negative charge on the leaving
c-phosphate that causes a disengagement of the interacting mo-
tifs. This would result in the conformation observed for MsbA
with ADP and vanadate. Asymmetric hydrolysis of ATP sup-
ported by the MsbA structure, would couple an alternating
catalytic cycle to the transport of drugs [38]. One possibility
is that asymmetric substrate binding to the TMDs would force
the deformation from two kinetically indistinguishable NBDse a-domain and b-domains are colored in tan and gray, respectively. P-
low), and L-loop (yellow) are shown. (B) ATP-bound homodimer from
e sphere) (1Z2R). The ICD1 helix is colored yellow. (D) MalK (1Q12).
esis. The image was created using the program Pymol.
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breaking the symmetrical conformation of the NBDs. The
breaking of the symmetry in the NBDs would then in turn drive
large conformational changes in the TMDs. A biochemical
study of the stochiometry between ATP and substrate in OpuA,
an osmoregulated ABC transporter, reveals that two ATPs are
required for the transport of one substrate. This is consistent
with the idea that the ﬁrst ATP is hydrolyzed during transport
and second ATP as a reset mechanism, restoring symmetry to
the nucleotide-binding sites [39,40]. An alternative to this mod-
el has been proposed whereby the binding of nucleotide rather
than ATP hydrolysis initiates drug transport [41–43].
A critical issue to the ABC transporter ﬁeld is the mecha-
nism of activation of ATP hydrolysis and the role that
substrate binding plays in this. Recent structural and biochem-
ical studies of speciﬁc mutations in the ATPase catalytic site
have begun to clarify the mechanism of activation. Mutation
of a conserved glutamate residue in the Walker B motif, desig-
nated the catalytic carboxylate, hinders the formation of the
closed conformation of the NBDs normally associated with
ATP binding [44]. A double mutant of this glutamate pro-
motes the formation of what is termed the occluded nucleotide
conformation in which an NBD dimer with tight ATP binding
is formed [45]. Substrate binding further promotes the forma-
tion of this conformation and the authors suggest that after
initial loose binding of ATP in the two NBDs, drug or sub-
strate binding drives the formation of the occluded conforma-
tion, with one tightly bound ATP committed to hydrolysis. In
the recent structure of the ATP Æ Mg2+ bound NBD dimer of
HlyB, Zaitseva et al. propose that an active site histidine
(H662 in HlyB, H537 in MsbA) coordinates with the catalytic
carboxylate glutamate to form a catalytic dyad critical for
accurate positioning of the nucleotide [30]. The available struc-
tural and biochemical data strongly suggest that both nucleo-
tide and substrate binding are required to position the active
site moieties to ensure the electrostatic and/or structural integ-
rity of the active site and contribute to the formation of an ac-
tive NBD dimer. We propose a step-wise activation of ABC
transporters through discrete conformational stages during
formation of the active NBD dimer. Thus, activation requires
conformational changes across the NBD dimer and TMD/
NBD interface that coordinates the positioning of catalytic res-
idues in both NBD active sites. Each stage provides a potential
control point in the translocation reaction at which regulation
by the various components can be exerted, thus ensuring the
binding and translocation of substrate at the appropriate time.
Clearly, signiﬁcant eﬀort will be required to bridge the gap be-
tween the structures of isolated NBDs, which provide atomic
resolution but are limited in the physiological interpretation,
and the medium resolution structure of these intact transport-
ers, which provide data on the domain architecture and con-
formational changes but lack the precision of side chain
positioning.5. Substrate speciﬁcity and translocation pathway
The role of the TMD is to recognize and mediate the passage
of substrates across cell membranes. For ABC transporters
that extrude hydrophobic or amphipathic molecules, the
TMD shields the polar groups of the substrates from the lipids
making up the bilayer, while accommodating the hydrophobicgroups to provide a pathway through the cell membrane. The
TMDs for drug and lipid ﬂippases are capable of recognizing
and removing a large number of chemically unrelated lipids
and toxins directly from the cell membrane [46]. The X-ray
structures of MsbA provide an initial framework to under-
stand the dynamic nature of the conformational changes in
the TMDs involved in mediating substrate transport.
The overall structural organization of MsbA was revealed in
two diﬀerent nucleotide free structures, one in an open
conformation and the other closed (Fig. 2A and B) [47,48].
These X-ray structures reveal a chamber formed from twelve
transmembrane a-helices. The open conformation exhibits
an inverted V shape with an opening accessible to the interior
of the transporter and dimer contacts concentrated between
the extracellular loops. In the closed conformation, the trans-
porter forms extensive contacts within the dimer interface of
the TMDs. In addition, the openings of the chamber are de-
ﬁned by intermolecular contacts between TM2 from one
monomer and TM5 from another. The chamber is lined with
charged and polar residues that are likely solvated, creating
an energetically favorable environment for polar moieties in
drug compounds and sugar groups from LPSs. The large size
of this polar chamber could give a structural basis for multi-
substrate speciﬁcity.
The recent X-ray structure of MsbA in complex with ADP,
orthovanadate and Ra LPS reveals a dramatic conformational
change in the TMDs that drives substrate transport. A large
torque of the TMDs accompanies this post-hydrolysis transi-
tion state, closing the cytoplasmic accessible chamber and
shifting the accessibility of this chamber to the extracellular
side of the cell membrane (Fig. 2C). LPS is bound to the mem-
brane-exposed sides of the protein at the dimer interface com-
posed of TM1, TM5 and TM6 from one monomer and TM2
from the other monomer. This binding site corresponds to a
hot-spot of conserved residues shared amongst P-gp, LmrA
and MsbA [34]. In addition, the conformational changes in
the TMDs are consistent with conformational changes ob-
served in P-gp after ATP hydrolysis [49].6. Mediating communication between NBDs and TMDs
A central question for ABC transporters is the mechanism of
transmitting substrate binding and ATP hydrolysis between
the NBDs and the TMDs. Based on the MsbA and BtuCD
structural work, we suggest that a conserved helix that extends
from the TMD segments into or near the active site of the
NBD is largely responsible for the inter-domain crosstalk. In
MsbA, the intercellular domain helix 1 (ICD1) (residues 97–
139), is in contact with the NBD and forms a U-like structure
consisting of three a-helices. The ﬁrst and third helices are
extensions of TM2 and TM3; the second helix of ICD1 rests
in the active site of the NBD and serves as a potential pivot
about which the NBD could rotate. BtuCD also has an analo-
gous structural motif mediating contact between the NBD and
the TMD [33]. However, in both the absence of substrate and
nucleotide, the ICD1-like motif in BtuCD is positioned out of
the active site. In the nucleotide-bound structure of MsbA, the
ICD1 contacts the Q-loop, which contains a conserved gluta-
mine. In the MJ0796 ATP-bound dimer structure, this gluta-
mine joins with a conserved glutamate from the Walker B
motif to coordinate a water positioned for nucleophilic attack
Fig. 2. X-ray crystal structures of MsbA. TMDs are colored green and blue, NBDs are colored magenta and orange. ICD1 helix is colored yellow.
(A) ‘‘Open’’ conformation of apo MsbA from E. coli (1JSQ). (B) ‘‘Closed’’ conformation of apo MsbA and V. cholera (1PF4). (C) ADP Æ Vi-bound
structure of MsbA from S. typhimurium with bound Ra LPS shown in magenta.
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communicate the catalytic state of the nucleotide to the TMDs
(Fig. 2B). Another interesting and more likely possibility is
that the presence of substrate is communicated through the
ICD1 helix to the NBDs which in turn promotes the correct
positioning of catalytic residues in the various conserved mo-
tifs present in the NBDs.7. Conformational dynamics of ABC transporters
Recent EPR studies of MsbA by Dong et al. [50], have
used site-directed spin labeling to characterize the conforma-
tional changes in apo and nucleotide bound forms of MsbA.
Accessibility to molecular oxygen and NiEDDA by 112 spin-
labeled mutants on TM2, TM5 and TM6 suggest that MsbA
is in a dynamic equilibrium of conformations that includes,
but is not limited to, the two apo X-ray structures. They also
observe a solvent ﬁlled chamber accessible to the cytoplasmic
ends of the TMDs in the absence of nucleotide, which is also
consistent with the apo structures. In addition, Buchaklian
et al. showed that site-directed spin labeling and cross-linking
results were consistent with the TMDs in the resting state
conformation of the MsbA observed in the apo crystal struc-
tures [51]. Electron microscopy structures of other putative
MDR-ABC transporters have also demonstrated that these
proteins can undergo signiﬁcant conformational changes.
The EM structure of the bacterial ABC transporter YvcC
from Bacillus subtilis has revealed an open conformation
that agrees well with the X-ray structure of the open apo-
state of MsbA and shows that the NBD can disengage from
the ICD during the catalytic cycle [52]. In addition, the EM
reconstruction of Pdr5p has also been determined [53] and
is consistent with the open apo structure of MsbA. Never-
theless, the physiological nature of the open apo conforma-
tion of these transporters remains controversial. The TMDscould sample such a large conformational space in order to
ﬁlter substrates from the lipid bilayer, but this might depend
on the speed of turnover of the transporter.
The X-ray structure of MsbA in complex with ADP and
vanadate shows that large conformational changes in the
TMDs are dependent on the nucleotide bound state of the
NBDs. In addition, the EM reconstruction structure of P-gp
in complex with the non-hydrolyzable analogue, AMPPNP
at 8 A˚ shows a domain organization similar to MsbA, and
an overall arrangement between the two halves that is more
consistent with the ADP Æ vanadate structure of MsbA than
either of the two apo structures [54]. The EM structure of P-
gp is also the ﬁrst structure of an intact ABC transporter to
show an asymmetric organization between the two TMD
halves but a symmetric dimer of NBDs, raising the interesting
question as to the mechanistic importance of this asymmetry in
the absence of bound translocation substrate.
The NBDs are also dynamic in nature. Puriﬁcation of iso-
lated NBDs is highly problematic in the absence of nucleotide
[55]. This empirical observation suggests, in combination with
the unfolded nature of the NBDs in the apo MsbA structures,
that the NBDs are intrinsically unstable in the apo form. The
concentration of nucleotide in the cell is suﬃciently high to
conclude that the NBDs would not sample such a large unfold-
ing between catalytic cycles as observed in the apo structures
of MsbA. However, disengagement of the NBDs from the
TMDs and a relaxation of the a and b subdomain packing
in the absence of nucleotide and/or substrate is possible. This
could provide a potential regulatory point during substrate
transport and would require discreet conformational changes
during drug/substrate binding, ATP binding, ATP hydrolysis
and nucleotide release.
One outstanding issue is the conformational changes associ-
ated with a catalytic transition state. Dong et al.s EPR studies
on the ATP-vanadate state shows a shift in accessibility of the
extracellular domains that is consistent with the post-hydroly-
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organization of the NBDs in the ADP-vanadate structure of
MsbA does not agree with a previous study by Fetsch and
Davidson [56] of vanadate induced photo-cleavage of the bac-
terial importer NBD subunit MalK, in which vanadate-
induced cleavage occurs in both the P-loop and LSGGQ
signature motif suggesting that the two motifs in MalK are
in close proximity to the nucleotide and vanadate ion. In the
current structure of MsbA, the P-loop and the signature motifs
are disengaged and an anomalous peak for the vanadate ion is
coordinated to the ADP but not in close proximity to the
LSGGQ signature motif of the opposite dimer.
We oﬀer a possible explanation for the discrepancy be-
tween the MalK studies and the MsbA studies. Hydrolysis
of ATP is a multi-step mechanism that results in discrete con-
formational changes in the NBDs. The inherent diﬀerences
within the various subgroups of ABC transporters (in partic-
ular between importers, like MalK, and exporters, like
MsbA), would amplify these conformational diﬀerences and
result in vanadate entering more favorably into the c-phos-
phate position at an earlier stage in the MalK case and in
a latter stage in the MsbA case. In addition, in MalK a C-ter-
minal domain increases the aﬃnity between MalK-NBD sub-
units. Upon examination of the MalK structure, it is evident
that this domain bridges the two interacting NBDs and im-
parts unique properties to this ABC importer (Fig. 1D).
Although most isolated NBDs purify as monomers in the ab-
sence of nucleotide, the MalK puriﬁes as a dimer [23]. Such a
signiﬁcant structural feature that stabilizes the dimeric form
of the MalK-NBDs, even in the absence of nucleotide, would
likely also play a role in stabilizing a closed dimer in the cat-
alytic transition state. This C-terminal domain is not present
in MsbA, P-gp or LmrA and therefore the observation of
vanadate cleavage in the LSGGQ motif of MalK may be
speciﬁc to NBDs with stabilizing domains that act to hold
the NBDs together. This may be an adaptation to ensure
ﬁdelity in the absence of a polypeptide tether between the
various subunits in most ABC importers.8. Model mechanism for substrate ‘‘ﬂipping’’
MDR-ABC transporters sequester lipid/drug molecules as
they diﬀuse through the cell membrane and either ﬂip them to
the outer leaﬂet or transport them into the extracellular milieu.
In order to accomplish this, they must ﬁrst recognize a diversity
of substrates, and then partially sequester the polar groups from
the membrane in a manner that would allow an energetically
favorable movement to the outer leaﬂet of the cellular mem-
brane. In our previous work, we presented a putative mecha-
nism where upon binding substrate, MsbA adopts a closed
conformation that traps the substrate within the chamber and
transports it exclusively through this chamber. However, the
structure ofMsbA in complex with LPS and nucleotide suggests
an alternative mechanism of substrate ‘‘ﬂipping’’.
We propose a model of substrate ‘‘ﬂipping’’ where the sugar
head groups of the LPS molecules are sequestered and then
diﬀuse across the membrane in the internal chamber of MsbA
while the hydrophobic tails of the lipid are dragged through
the bilayer. We have extended this mechanism to encompass
drug compounds involved with MDR, which also have theproperty of being amphipathic. Based on a locus of conserved
residues between MsbA, LmrA and P-gp and residues that
have been identiﬁed in drug binding studies for P-gp (for a de-
tailed examination please see, [49,57]), we propose that sub-
strate initially binds near the elbow helix. During the ‘‘power
stroke’’, the polar groups are sequestered within the chamber
and moved to the outer leaﬂet of the membrane by the rigid
body shearing of the TMDs while the hydrophobic groups
are dragged through the lipid bilayer. There also may be more
than one pathway through the dimer. The internal reorienta-
tion of the TM5 and TM6 upon ATP hydrolysis may act as
a gate allowing the substrate to move from the inner leaﬂet
to the outer leaﬂet, through channels on either side of the cen-
tral pore.9. Concluding remarks
The recent X-ray structures of MsbA together with bio-
physical and biochemical studies provide insight into the
conformational ﬂexibility and mechanistic properties of
MDR ABC transporters. However, many critical issues still
remain: (i) What are the speciﬁc molecular components that
direct signal through the ICD1 helix to the NBD active site?
Is this substrate-driven or nucleotide-driven or both? Is this
conserved in the entire ABC transporter family? (ii) What
are the discrete conformational changes in the NBD dimer
that are associated with the various stages of ATP hydroly-
sis? If substrate binding initiates hydrolysis of ATP in an
asymmetric manner, and two ATP molecules are hydrolyzed
per single substrate transported, how is hydrolysis initiated
in the second NBD? (iii) What is the conformation of the
TMDs in the ATP dimer state? Is this the transport ‘‘power
stroke’’? Structural and biochemical studies must be directed
at these and other key questions to further drive our under-
standing for this class of clinically important integral mem-
brane proteins.
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